NovoCure NVCR Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $87.53M-31.2% | $93.55M-42.9% | $342.12M+84.5% | $149.62M-9.2% | $127.28M-72.0% | ||
| $344.48M-57.0% | $354.13M-55.5% | $691.38M-10.7% | $761.9M-3.1% | $801.85M+92.6% | ||
| $9.8M+355% | $9.84M+323% | $2.52M-33.3% | $2.51M-31.2% | $2.15M-40.2% | ||
| $43.46M+10.1% | $41.11M+17.2% | $39.1M0.0% | $40.21M-0.6% | $39.47M-6.9% | ||
| $631.66M-42.0% | $646.73M-41.6% | $1.2B+9.5% | $1.08B-0.9% | $1.09B+8.6% | ||
| $76.28M-4.2% | $77.61M-0.1% | $79.98M+9.2% | $80.33M+20.8% | $79.6M+35.1% | ||
| $45.48M-6.3% | $47.33M+74.5% | $48.4M+70.9% | $48.09M+65.4% | $48.51M+47.0% | ||
| $11.2M-22.7% | $10.6M-27.5% | $12.41M+1.5% | $15.56M+29.0% | $14.48M-2.8% | ||
| $156.26M-2.0% | $157.6M+17.4% | $161.34M+27.3% | $162.58M+36.2% | $159.51M+34.4% | ||
| $787.93M-36.9% | $804.33M-35.2% | $1.36B+11.4% | $1.25B+2.8% | $1.25B+11.4% | ||
| $127.24M+33.8% | $122.23M+16.3% | $118.92M+30.2% | $103.68M+15.0% | $95.09M+12.8% | ||
| $217.58M-70.7% | $223.23M-70.5% | $776.01M+5.6% | $749.63M+343% | $743.31M+364% | ||
| $39.48M-2.1% | $41.65M+109% | $42.68M+102% | $42.85M+97.2% | $40.31M+57.4% | ||
| $239.63M+66.9% | $240.63M+93.7% | $243.86M+93.2% | $146.8M-78.5% | $143.55M-76.1% | ||
| $457.21M-48.4% | $463.86M-47.3% | $1.02B+18.4% | $896.43M+5.4% | $886.85M+16.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $1.7B+9.2% | $1.63B+7.5% | $1.61B+10.9% | $1.58B+11.3% | $1.55B+12.0% | ||
| -$1.36B-14.6% | -$1.29B-11.8% | -$1.27B-16.3% | -$1.23B-16.2% | -$1.19B-16.0% | ||
| -$4.9M-16.5% | -$3.44M+37.4% | -$5.81M-8.0% | -$5.11M-45.3% | -$4.2M-1.3% | ||
| $330.72M-8.6% | $340.47M-5.5% | $341.33M-5.4% | $349.44M-3.4% | $361.96M+0.7% | ||
| $787.93M-36.9% | $804.33M-35.2% | $1.36B+11.4% | $1.25B+2.8% | $1.25B+11.4% | ||
| —— | —— | —— | —— | —— | ||
| $53.13M+56.1% | $58.67M+67.3% | $39.5M+55.3% | $39.14M+19.1% | $34.04M+58.5% | ||
| $11.2M-22.7% | $10.6M-27.5% | $12.41M+1.5% | $15.56M+29.0% | $14.48M-2.8% | ||
| $45.48M-6.3% | $47.33M+74.5% | $48.4M+70.9% | $48.09M+65.4% | $48.51M+47.0% | ||
| $23.31M+37.8% | $22.07M+49.0% | $20.55M+59.1% | $18.59M+58.6% | $16.91M+42.0% | ||
| $45.48M-6.3% | $47.33M+74.5% | $48.4M+70.9% | $48.09M+65.4% | $48.51M+47.0% | ||
| $11.2M-22.7% | $10.6M-27.5% | $12.41M+1.5% | $15.56M+29.0% | $14.48M-2.8% | ||
| $45.48M-6.3% | $47.33M+74.5% | $48.4M+70.9% | $48.09M+65.4% | $48.51M+47.0% | ||
| $11.2M-22.7% | $10.6M-27.5% | $12.41M+1.5% | $15.56M+29.0% | $14.48M-2.8% | ||
| $90.34M+1.2% | $101M+8.4% | $96.46M+11.7% | $86.17M+9.1% | $89.25M+17.6% | ||
| $195.46M+101% | $195.05M+100% | $194.64M+100% | $97.61M+0.7% | $97.45M— | ||
| $39.48M-2.1% | $53.31M+91.2% | $42.68M+102% | $42.85M+97.2% | $40.31M-93.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $4.69M-18.7% | $3.94M-43.3% | $6.52M-17.4% | $6.32M+4.9% | $5.77M-12.2% | ||
| $195.46M+101% | $195.05M+100% | $194.64M+100% | $97.61M+0.7% | $97.45M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can NovoCure cover its short-term obligations?
- Its current ratio is 2.90 — current assets exceed current liabilities.
- Where does NovoCure's balance sheet data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.